目的 检测三阴乳腺癌（TNBC） 组织中C-myc和Skp2的表达情况及其意义。 方法 选取2008年1月－2011年12月手术切除的TNBC标本56例，采用免疫组织化学链霉素抗生物素蛋白-过氧化物酶连结法检测它们和30例癌旁正常乳腺组织中C-myc和Skp2的表达情况。 结果 TNBC组织中C-myc和Skp2表达定位于细胞核，其表达率分别为57.14%（32/56） 和58.93%（33/56），明显高于癌旁正常组织（P＜0.05）；56例TNBC组织中，C-myc和Skp2蛋白在组织学分级Ⅲ级表达率高于Ⅰ+Ⅱ级（P＜0.05）；C-myc和Skp2的病理分期Ⅲ期的表达率高于Ⅰ-Ⅱ期（P＜0.05）；表达率高低与腋窝有无淋巴结转移有关（P＜0.05），而与病理组织类型无关（P＞0.05）；相关性分析显示，C-myc和Skp2二者之间呈正相关（P＜0.05）。 结论 C-myc和Skp2在TNBC中呈明显高表达，与TNBC的发生、发展和转移密切相关。
Objective To explore the characters and therapy of the triple-negative breast cancer （TNBC）. Methods The pertinent literatures with key words “triple-negative breast cancer”，“diagnosis”，and “therapy” were retrieved and reviewed. Results TNBC was a subtype of breast cancer characterized by negative expressions of estrogen receptor （ER），progesterone receptor （PR），and human epidermal growth factor receptor-2 （HER-2）. The clinicopathologic feature and prognosis of TNBC were distinct from other breast cancer. The age of onset was younger，disease free survival and total survival rate were lower in the patients with TNBC. At present， the therapy guideline was lack of TNBC，which referred to the non-TNBC，including local surgery，systemic chemotherapy，and the target therapy was at the clinical trial stage. Conclusions TNBC is one of heterogeneity characteristics for the breast cancer，which has extra much difference. For improving the TNBC prognosis，we hope that more and more significant markers to TNBC in the future are found，which are useful to make individuation treatment.
Oncogene StarD4 had the function of promoting proliferation and metastasis of triple-negative breast cancer (TNBC), but its clinical value and molecular mechanism are unknown. This paper found that StarD4 was highly expressed in cancer tissues of TNBC patients, and higher expression level of StarD4 in TNBC patient resulted in poorer prognosis. Based on transcriptomics of MDA-MB-231 cell model, the results of bioinformatics analysis showed that down-regulated expression level of StarD4 led to overall downregulation of cholesterol-relative genes and significant enrichment of cancer mechanism and pathway. Further analysis and investigation verified that StarD4 might cross-promote the protein stability of receptor ITGA5 through the cholesterol pathway to enhance TNBC progression, which provides guidance for clinical application of TNBC diagnosis and treatment.